AVTX Avalo Therapeutics, Inc.
Avalo Therapeutics, Inc. (AVTX) Insider Activity
What the officers, directors and large holders did with their own shares. Only open-market purchases and sales count toward the totals — grants, option exercises and shares withheld for tax are compensation mechanics, not decisions, and they're listed separately below.
How much of that selling was preplanned? 86% planned / 14% discretionary
Largest single sale: $952.7K.
Where they traded
No open-market insider purchase on record.
Recent open-market activity
| Date | Insider | Role | Action | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|---|
| Sullivan Christopher Ryan | Chief Financial Officer | Sell 10b5-1 | 10,185 | $17.62 | $179.5K | 39,900 −20.3% of holding | |
| Doyle Mittie | Chief Medical Officer | Sell 10b5-1 | 679 | $20.00 | $13.6K | 51,776 −1.3% of holding | |
| Sullivan Christopher Ryan | Chief Financial Officer | Sell | 31,031 | $20.05 | $622.3K | 39,900 −43.7% of holding | |
| Sullivan Christopher Ryan | Chief Financial Officer | Sell 10b5-1 | 37,945 | $19.85 | $753.3K | 43,649 −46.5% of holding | |
| Sullivan Christopher Ryan | Chief Financial Officer | Sell | 3,749 | $19.94 | $74.8K | 39,900 −8.6% of holding | |
| Doyle Mittie | Chief Medical Officer | Sell 10b5-1 | 1,000 | $20.00 | $20.0K | 51,776 −1.9% of holding | |
| Riley Jennifer | Chief Strategy Officer | Sell | 2,655 | $19.59 | $52.0K | 37,041 −6.7% of holding | |
| Doyle Mittie | Chief Medical Officer | Sell 10b5-1 | 679 | $20.00 | $13.6K | 51,776 −1.3% of holding | |
| Doyle Mittie | Chief Medical Officer | Sell 10b5-1 | 1,000 | $20.00 | $20.0K | 51,776 −1.9% of holding | |
| Doyle Mittie | Chief Medical Officer | Sell 10b5-1 | 4,654 | $20.00 | $93.1K | 51,776 −8.2% of holding | |
| Doyle Mittie | Chief Medical Officer | Sell 10b5-1 | 1,450 | $18.00 | $26.1K | 51,776 −2.7% of holding | |
| Doyle Mittie | Chief Medical Officer | Sell 10b5-1 | 679 | $16.00 | $10.9K | 47,122 −1.4% of holding | |
| Doyle Mittie | Chief Medical Officer | Sell 10b5-1 | 3,000 | $18.76 | $56.3K | 3,622 −45.3% of holding | |
| Sullivan Christopher Ryan | Chief Financial Officer | Sell 10b5-1 | 18,606 | $24.12 | $448.8K | 423 −97.8% of holding | |
| Doyle Mittie 5 fills | Chief Medical Officer | Sell 10b5-1 | 106,555 | $20.68 | $2.2M | 82,639 −56.3% of holding | |
| VARKI PAUL 5 fills | Chief Legal Officer | Sell 10b5-1 | 75,063 | $20.17 | $1.5M | 41,322 −64.5% of holding | |
| Sullivan Christopher Ryan 5 fills | Chief Financial Officer | Sell 10b5-1 | 47,000 | $20.19 | $948.7K | 33,589 −58.3% of holding | |
| Chan Mitchell | Director | Sell 10b5-1 | 3,167 | $22.88 | $72.5K | 3,166 −50% of holding | |
| Doyle Mittie | Chief Medical Officer | Sell 10b5-1 | 1,679 | $16.00 | $26.9K | 3,622 −31.7% of holding | |
| Sullivan Christopher Ryan | Chief Financial Officer | Sell 10b5-1 | 8,457 | $13.23 | $111.9K | 423 −95.2% of holding | |
| Sullivan Christopher Ryan | Chief Financial Officer | Sell 10b5-1 | 8,458 | $13.09 | $110.7K | 8,880 −48.8% of holding | |
| Doyle Mittie | Chief Medical Officer | Sell 10b5-1 | 3,970 | $18.01 | $71.5K | 3,622 −52.3% of holding | |
| Sullivan Christopher Ryan 2 fills | Chief Financial Officer | Sell 10b5-1 | 7,980 | $17.15 | $136.8K | 19,118 −29.4% of holding | |
| Sullivan Christopher Ryan 2 fills | Chief Financial Officer | Sell 10b5-1 | 7,979 | $16.77 | $133.8K | 32,797 −19.6% of holding | |
| Doyle Mittie | Chief Medical Officer | Sell 10b5-1 | 679 | $16.00 | $10.9K | 3,622 −15.8% of holding | |
| Doyle Mittie | Chief Medical Officer | Sell | 25,492 | $16.15 | $411.6K | 3,622 −87.6% of holding |
Form 4s are due within two business days of a transaction, so this is close to real time — unlike the quarterly 13F data on the Institutional tab. A single large sale often reflects a prearranged 10b5-1 plan rather than a fresh view, so read a pattern of sales rather than any one of them.